Bio-Techne (TECH) Tops Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2022 RESULTS
May 4, 2022 6:30 AM EDTMINNEAPOLIS, May 4, 2022 /PRNewswire/ --Â Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2022.
Third Quarter FY2022 Highlights
Third quarter organic revenue increased by 17% (19% reported) to $290.4 million and 18% (22% reported) in the first nine months of fiscal 2022 to $817.4 million. GAAP EPS was $1.48 versus $1.12 one year ago. Delivered record adjusted earnings per share (EPS) of $2.14 versus $1.80 one year ago. Excellent commercial execution in both operating segments with Protein Sciences delivering organic growth of 16% (15% reported) and Diagnostics and Genomics achieving 19% (34% reported) organic growth.... More


